Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 19% increase in EPS and improved margins. Management expressed optimism about clinical growth and incremental instrument placements, despite not raising organic growth guidance. The Q&A section reassures strong demand and no market freezing, with expectations of margin improvements later in the year. Although some vague responses were noted, the overall sentiment is positive with raised guidance and strategic growth in clinical and spatial markets.
Key Financial Performance
Revenue $1.09 billion, up 4.8% year-over-year and 1.2% on an organic basis. Growth driven by better-than-expected instrument sales and clinical consumable sales.
Rest of World Organic Growth 3.5%, driven by strength in sequencing consumables and instruments.
Sequencing Consumables Revenue $726 million, up 4% year-over-year. Growth driven by high throughput volume and increased utilization of NovaSeq X.
Clinical Sequencing Consumables Growth 20% growth ex China for the second consecutive quarter. Driven by expansion of clinical volumes and adoption of sequencing-intensive tests.
Sequencing Instruments Revenue $118 million, up 9% year-over-year. Growth driven by increased sales of NovaSeq X.
Sequencing Service and Other Revenue $151 million, up 7% year-over-year. Growth driven by scaling up BioInsight and strategic partnerships.
Microarrays Business Revenue Down 20% on a Rest of World organic basis. Decline due to specific large customers in the direct-to-consumer segment.
Non-GAAP Gross Margin 68.2%, up 80 basis points year-over-year. Improvement driven by cost efficiencies and higher revenue.
Non-GAAP Operating Expenses $506 million, up 3% year-over-year. Increase largely reflects the addition of SomaLogic team.
Non-GAAP Operating Margin 21.9%, up approximately 150 basis points year-over-year. Improvement due to increased operating leverage from improved cost structure.
Non-GAAP EPS $1.15 per diluted share, up approximately 19% year-over-year. Growth driven by higher revenue and improved margins.
Free Cash Flow $251 million for Q1. Reflects strong cash flow provided by operations and controlled capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NovaSeq X placements: Over 80 NovaSeq X placements in Q1, approximately 20 more than Q1 '25, with year-over-year placements growth in both clinical and nonclinical markets. New high-volume clinical applications are being built on the NovaSeq X as the platform becomes more embedded in clinical workflows and supports continued consumables growth over time.
TruPath launch: Launched TruPath, enabling whole genome sequencing with deeper insight while eliminating traditional library prep, reducing hands-on time to about 10 minutes. Significant interest from customers, particularly in areas like rare disease.
Spatial transcriptomics offering: High engagement around spatial transcriptomics offering, generating data in challenging sample types like lymphatic tissue. On track to launch later this year.
NovaSeq X platform improvements: Introduced 18-month road map including new 14B and 35B flow cells, staggered flow cells run, and improved data quality with Q70 performance. These innovations offer more flexibility, increase throughput, and improve workflow efficiency.
Clinical market growth: Clinical made up more than 65% of sequencing consumables revenue in Q1, driven by expansion of sequencing-based diagnostics and increased use of data-intensive applications. Clinical sequencing consumable demand grew 20% ex China for the second consecutive quarter.
Research and academic markets: Demand remains cautious due to funding uncertainty, but long-term opportunities are expected as funding stabilizes. Investments continue in proteomics, single cell, and spatial technologies.
Revenue and margin performance: Q1 revenue of $1.09 billion, up 4.8% year-over-year. Margins approximately 150 basis points above guidance due to disciplined expense management and strong revenue performance.
Operational efficiency: Non-GAAP operating margin expanded approximately 150 basis points year-over-year, reflecting improved cost structure and operating leverage.
SomaLogic acquisition: Successfully closed the SomaLogic acquisition, with the business performing in line with expectations on both revenue and profitability.
BioInsight and Billion Cell Atlas: BioInsight introduced to accelerate discovery, with the Billion Cell Atlas program generating insights for AI-driven drug discovery models. Growing interest from partners and companies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Research and Academic Market Demand: Demand in research and academic markets remains cautious due to funding uncertainty, which could impact revenue growth in these segments.
Supply Constraints for NovaSeq X: The company faced supply constraints for NovaSeq X units in Q1, which could limit the ability to meet strong demand and impact revenue.
Inflationary Pressures: Near-term inflationary pressures related to freight costs and higher costs of electronic components are affecting operating margins.
Microarrays Business Decline: The microarrays business experienced a 20% decline on a Rest of World organic basis, largely due to specific large customers in the direct-to-consumer segment.
Regulatory and Reimbursement Challenges: Progress in reimbursement for sequencing-based diagnostics is ongoing, but delays or challenges in this area could impact broader adoption and revenue growth.
Economic and Funding Uncertainty: Uncertainty in the macroeconomic environment and funding for research and applied markets could continue to affect demand and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Illumina has raised its full-year 2026 revenue guidance to $4.52 billion to $4.62 billion, reflecting Q1 outperformance. Acquired revenue is expected to contribute 1.5 to 2 points of growth, and currency is expected to add approximately 1% of growth. Rest of World organic growth is projected at 2% to 4%.
Clinical Market Growth: Clinical markets are expected to grow double-digit to mid-teens, driven by increased adoption of sequencing-based diagnostics and more sequencing-intensive applications. Clinical sequencing consumable demand is projected to expand significantly.
Research and Applied Markets: Research and applied markets are expected to decline mid- to high single digits due to funding uncertainties. However, a return to growth is anticipated as funding conditions improve.
NovaSeq X Demand: Strong demand for NovaSeq X instruments is expected to continue, with supply constraints being addressed. The company has raised its instrument guidance to flat to low single-digit growth year-over-year.
Operating Margins and EPS: Operating margins for 2026 are expected to be between 23.4% to 23.6%, representing approximately 140 basis points of year-over-year margin expansion. Non-GAAP diluted EPS guidance has been raised to $5.15 to $5.30, reflecting 12% growth at the midpoint, excluding the impact of acquisitions.
Q2 2026 Guidance: For Q2 2026, Illumina expects Rest of World organic revenue growth of 4% to 6%, reported revenue of $1.12 billion to $1.14 billion, and non-GAAP EPS of $1.20 to $1.25. Operating margins are projected at approximately 22%.
2027 Long-Term Targets: Illumina remains on track to achieve its 2027 targets, including high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. The company aims for approximately 350 basis points of margin expansion by the end of 2026, progressing towards a 500 basis point target by 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Authorization: Illumina's Board of Directors has authorized an additional $1.5 billion in share repurchases.
Share Repurchase Activity: In Q1, Illumina repurchased 2 million shares of its stock for approximately $242 million at an average price of $120.85 per share.
Remaining Authorization: At the end of Q1, Illumina had approximately $400 million remaining on its current share repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why wasn't the annual organic growth guidance raised despite strong Q1 performance?
A:Management expressed optimism about continued momentum in the clinical business and strong instrument placements. However, they noted that it is still early in the year and emphasized that they are signaling positive trends by raising both top-line and bottom-line guidance early in the year.
Q:What is driving the strong momentum in instrumentation, and how does it impact the guidance?
A:Management highlighted strong placements in Q1 and Q4, with over 60% of placements in the clinical space. They noted that these placements are incremental rather than conversions and are expected to drive consumables revenue. They also mentioned that pricing transitions are already incorporated into the guidance.
Q:Can you quantify the backlog and address concerns about market freezing?
A:Management stated that there is no market freezing and emphasized strong demand and a robust pipeline. They noted that performance obligations are up more than 20% year-over-year, and Q2 placements are expected to be close to Q1 levels.
Q:How should we think about operating margin progression throughout the year?
A:Management acknowledged some headwinds, including inflationary pressures and investments to scale supply. They expect mitigating actions to take effect in Q3 and Q4, leading to an improvement in operating margins in the second half of the year.
Q:What is the status of the NovaSeq X customer conversion and its impact on clinical growth?
A:Management noted that some clinical customers are transitioning to the NovaSeq X platform, while others remain on the 6K platform due to regulatory or operational reasons. They expect the transition to be largely complete by the end of the year, with a long tail of transitions continuing.
Q:What is the outlook for research and applied markets?
A:Management expects the research market to improve later in the year due to NIH funding but remains cautious. They noted that most of the pricing headwinds have been addressed, and any improvement in the research market would be considered upside to the guidance.
Q:Can clinical growth exceed the guidance range?
A:Management expressed confidence in mid-teens growth for the clinical market and noted that any growth beyond that would be considered upside to the guidance.
Q:Did the guidance update reflect competitive pressures, such as pricing from competitors?
A:Management stated that they are confident in their competitive position and have incorporated their expectations into the guidance. They emphasized their focus on driving consumables growth through instrument placements.
Q:What is the pricing strategy for the NovaSeq X and its impact on demand?
A:Management emphasized the importance of driving consumables growth through NovaSeq X placements. They acknowledged offering volume discounts for large orders and noted that some placements are under reagent or lease models, which have different revenue recognition patterns.
Q:What is the outlook for low and mid-throughput instruments?
A:Management reported strong momentum for the MiSeq i100 in the low-throughput segment but noted challenges in the mid-throughput segment due to macroeconomic factors. They expect the mid-throughput market to improve when the research market recovers.
Q:What is driving demand for the NovaSeq X in the clinical market?
A:Management highlighted broad interest across oncology, rare disease, and NIPT applications. They noted strong demand from centralized labs in the U.S. and emphasized the opportunity for growth in the clinical space.
Q:What is Illumina's strategy in the spatial market?
A:Management expressed excitement about their spatial solution and noted that it addresses a different customer segment compared to competitors. They believe there is room for multiple players in the spatial market and are confident in their offering.
Q:Review of Unclear Management Responses
A:Management avoided providing specific pricing details for the 35B flow cell and did not quantify the inflationary pressures from memory chips and freight. Additionally, they used vague language when discussing the potential upside in clinical growth and the impact of competitive pressures on guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AGBT TruPath
AGBT end
AI
Ankur detail
Ankur review
Atlas gene
BioInsight Cell
BioInsight discovery
Cell Atlas
China focus
Clinical consumables
Clinical research
Conor measure
Customer interest
Illumina
NovaSeq placement
NovaSeq role
RD
World
application NovaSeq
area
cost environment
diagnostics
example
expansion
expectation outlook
flow cell
funding uncertainty
future
outperformance
platform
quality reliability
reporting
road map
sample
start
success
track
type
ILMN Transcript
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call highlights strong financial performance with a 19% increase in EPS and improved margins. Management expressed optimism about clinical growth and incremental instrument placements, despite not raising organic growth guidance. The Q&A section reassures strong demand and no market freezing, with expectations of margin improvements later in the year. Although some vague responses were noted, the overall sentiment is positive with raised guidance and strategic growth in clinical and spatial markets.
Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary and Q&A indicate strong financial performance with 16% EPS growth and improved margins. Despite challenges in Greater China, the overall growth outlook is optimistic, especially with high single-digit revenue growth and strategic transitions like NovaSeq X. The Q&A reveals confidence in achieving long-term targets and strong demand in clinical markets. The lack of detailed M&A criteria and cautious guidance for 2026 are minor concerns, but the positive aspects outweigh these, suggesting a positive stock price movement.
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
ILMN Slides
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances2026-02-05
Illumina Q2 2025 slides: Revenue dips 3% while EPS grows 9% amid NovaSeq X transition2025-10-30
Illumina Q2 2025 slides: revenue declines 3% while margins expand, SomaLogic acquisition announced2025-07-31
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts2025-05-08
ILMN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
